<DOC>
	<DOCNO>NCT02700100</DOCNO>
	<brief_summary>The study prospective , non-randomised , open label clinical study ass safety Bioabsorbable Pulmonary Valved ( PV ) conduit ( PV-001 ) subject &gt; 2 year &lt; 22 year age , undergo Right Ventricular Outflow Tract ( RVOT ) reconstruction . It first man feasibility study include 10-12 patient 6 site Europe . The primary objective study assess survival rate subject 6 month follow implantation Bioabsorbable Pulmonary Valved Conduit ( PV-001 ) . Secondary objective : 1 . The survival rate subject 12 month follow implantation Bioabsorbable Pulmonary Valved Conduit ( PV-001 ) 2 . The percentage conduit failure 6 month 12 month , conduit failure include need reintervention reoperation . 3 . The pressure gradient across pulmonary valve acceptable level 12 month follow . 4 . The pulmonary regurgitation measure exceed moderate grade 12 month follow . 5 . To evaluate usability Bioabsorbable Pulmonary Valved Conduit ( PV-001 ) surgical procedure , use exploratory parameter Long term safety assess 60 month post implantation .</brief_summary>
	<brief_title>Study Assess Safety Pulmonary Valved Conduit ( PV-001 ) Subjects Undergoing Right Ventricular Outflow Tract Reconstruction</brief_title>
	<detailed_description />
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Heart Defects , Congenital</mesh_term>
	<criteria>1 . Patient require RVOT reconstruction , suitable 16 mm 18 mm conduit . 2 . Male Female . 3 . Age &gt; 2 year &lt; 22 year . 4 . Right Ventricular Pulmonary Artery peak gradient &gt; 35mm Hg moderate severe Pulmonary Valve regurgitation ( â‰¥3+ ) , . 5 . The patient , patient 's parent / legal representative appropriate , informed nature study , agree provision provide write informed consent sign approve informed consent form . 6 . The patient , patient 's parent / legal representative appropriate , treat physician agree subject return require postprocedure follow visit subject comply protocolrequired followup visit . 1 . Need presence prosthetic valve position . 2 . Need concomitant surgical procedure ( outside heart ) . 3 . Patients previously implant pacemaker ( include defibrillator ) , mechanical valve . 4 . Active infection require current antibiotic therapy ( temporary illness , subject may candidate 4 week discontinuation antibiotic ) . 5 . Active endocarditis . 6 . Leukopenia . 7 . Acute chronic anaemia . 8 . Thromocytopenia . 9 . Severe chest wall deformity . 10 . Right ventricular outflow tract aneurysm . 11 . Known hypersensitivity anticoagulant antiplatelet drug . 12 . Immunocompromised patient define : autoimmune disease , patient receive immunosuppressant drug immunostimulant drug . 13 . Need emergency cardiac vascular surgery intervention . 14 . Major progressive noncardiac disease ( liver failure , renal failure , cancer ) life expectancy le one year . 15 . Currently participate , participate within last 30 day , investigational drug device study . 16 . Alcohol drug abuse define DSM IVTR criterion substance abuse include illicit use cannabis within last 12 month . 17 . Pregnancy . 18 . Females sexually active willing use adequate contraceptive precaution next 2 year 19 . Subject medical , social psychosocial factor , opinion Investigator , could impact safety compliance study procedure .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>